8-K: Y-mAbs Therapeutics Reports Mixed Q1 2024 Results, DANYELZA Sales Show Growth in US

Y-mAbs Therapeutics reported a mixed first quarter of 2024, with US DANYELZA sales increasing by 11% year-over-year, while worldwide sales decreased by 4% due to international factors.

Summary

• Y-mAbs Therapeutics announced its financial results for the first quarter of 2024, ending March 31, 2024.
• The company reported U.S. DANYELZA net product revenues of $18.6 million, an 11% increase year-over-year.
• Worldwide DANYELZA net product revenues were $19.4 million, a 4% decrease year-over-year, primarily due to lower international sales.
• The company's cash and cash equivalents stood at $75.7 million as of March 31, 2024, with a cash burn of $2.9 million for the quarter.
• Management has reiterated its full-year 2024 financial guidance and anticipates a cash runway into 2027.
• The company experienced a net loss of $6.6 million, or $0.15 per share, which is relatively flat compared to the same period last year.
• The company's gross margin remained consistent at approximately 89%.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to strong US sales growth and reaffirmed guidance, but tempered by the decrease in international sales and a net loss. The company's cash runway into 2027 provides some reassurance.

Positives

• U.S. DANYELZA sales showed strong growth, increasing by 11% year-over-year.
• The company's cash burn was relatively low at $2.9 million for the quarter.
• Management has reiterated its full-year 2024 financial guidance, indicating confidence in future performance.
• The company's cash runway is expected to extend into 2027, providing financial stability.
• The company added five new DANYELZA accounts in the U.S. during the quarter, expanding its reach.
• The company's gross margin remained strong at approximately 89%.

Negatives

• Worldwide DANYELZA net product revenues decreased by 4% year-over-year.
• International DANYELZA net product revenues decreased significantly due to a prior year stocking shipment.
• The company reported a net loss of $6.6 million for the quarter.
• Total DANYELZA net product revenues decreased by 17% compared to the fourth quarter of 2023.

Risks

• The company's international sales are subject to fluctuations and can be impacted by stocking shipments.
• The company's cash runway estimate is based on assumptions that may prove to be inaccurate.
• The company is dependent on the success of DANYELZA and its pipeline products.
• The company faces risks related to regulatory approvals and commercialization of its products.
• The company's future financial performance is subject to various market and economic conditions.

Future Outlook

Management anticipates that current cash and cash equivalents, along with expected DANYELZA product revenues, will support operations into 2027. The company also expects higher international sales volumes to resume in future quarters of 2024.

Management Comments

• Mike Rossi, President and Chief Executive Officer, stated that the first quarter of 2024 marked the highest quarter of U.S. demand for DANYELZA since its initial launch.
• Mike Rossi also expressed encouragement regarding the clinical advancement of the company's Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy (PRIT) Technology platform.

Industry Context

The company operates in the biopharmaceutical industry, focusing on cancer treatments. The results reflect the challenges and opportunities in commercializing novel therapies, particularly in the context of global market dynamics and competition. The company's focus on radioimmunotherapy and antibody-based therapeutics aligns with current trends in cancer treatment.

Comparison to Industry Standards

• Y-mAbs's 11% year-over-year growth in U.S. DANYELZA sales is a positive sign, but the 4% decrease in worldwide sales highlights the challenges of international market penetration, which is a common issue for biopharmaceutical companies.
• The company's cash burn of $2.9 million for the quarter is relatively low compared to other companies in the sector, which often have higher cash burn rates due to extensive R&D and clinical trial costs.
• The company's gross margin of 89% is strong, indicating efficient cost management in manufacturing and distribution.
• Companies like BioMarin Pharmaceutical Inc. and Sarepta Therapeutics, Inc. also focus on rare diseases and have faced similar challenges in balancing domestic and international sales growth.
• The company's SADA PRIT technology is a novel approach, and its success will be crucial for future growth, similar to how CAR-T cell therapies have become a significant area of focus for companies like Gilead Sciences and Novartis.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may be encouraged by the growth in U.S. sales and the reaffirmed financial guidance, but concerned about the net loss and decrease in international sales.
• Employees may be affected by the ongoing search for a new CFO and the company's restructuring efforts.
• Customers (healthcare providers and patients) may benefit from the continued availability and potential expansion of DANYELZA.
• Suppliers may be impacted by the company's financial performance and future growth plans.
• Creditors may be reassured by the company's cash runway into 2027.

Next Steps

• The company will host a conference call on May 8, 2024, to discuss the results.
• The company will present abstracts at the 2024 ASCO Annual Meeting from May 31 through June 4, 2024.
• The company will continue to focus on the commercialization of DANYELZA and the development of its SADA PRIT technology.
• The company will continue the search for a new Chief Financial Officer.

Key Dates

Keywords

DANYELZA, Y-mAbs, Neuroblastoma, Radioimmunotherapy, SADA PRIT, Financial Results, Biopharmaceutical, Cancer Therapy, Net Product Revenue, Cash Burn